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Regulation of autophagy by proteolytically cleaved fragments of
heparan sulfateproteoglycans is anovel andcurrent research focus
in tumor biology. Endorepellin is the C-terminal angiostatic frag-
ment of the heparan sulfate proteoglycan perlecan and induces
autophagy inendothelial cells.To further investigate thisproperty,
we used NanoString, a digital PCR platform for measuring pre-
definedtranscripts inbiological samples toanalyzeacustomsubset
of 95autophagy-relatedgenes inhumanumbilical veinendothelial
cells treatedwith ultrapure human recombinant endorepellin.We
discovered an endorepellin-evoked pro-autophagic and pro-mi-
tophagic gene expression signatures, which included two coordi-
nately up-regulated mitochondrial-associated genes encoding the
E3 ubiquitin protein ligase Parkin and the tumor suppressormito-
statin. Induction of both proteins required the tyrosine kinase
activityof vascular endothelial growth factor receptor2 (VEGFR2).
Furthermore, we discovered that endorepellin evoked mitochon-
drial depolarization in endothelial cells via a specific interaction
between its two proximal LG1/2 domains and VEGFR2. We also
found that following loss of membrane potential, mitostatin and
parkin interact and that mitostatin associates with the established
Parkin receptor mitofusin-2. In conclusion, we have identified a
critical role for endorepellin in remodeling the autophagic tran-
scriptome and influencingmitochondrial homeostasis.
Autophagic regulation by proteolytically cleaved fragments
of heparan sulfate proteoglycans (HSPGs)2 represent a novel
thread of research in tumor biology (1–6) and may represent
viable and novel therapeutic opportunities (7) outside conven-
tional roles of the heparan sulfate chains (8–11). Perlecan,
which encompass one of the largest multimodular HSPGs
found in vascular basementmembranes (12–18) and the osteo-
cyte pericellular matrix (19), exhibits angiogenic bivalency
by fine-tuning pro- and anti-angiogenic signals (20–22).
Endorepellin, the C-terminal domain of perlecan, exhibits
potent angiostatic properties (23) and is antithetic in function
to the N-terminal HS chains required for growth factor seques-
tration and co-receptor activity (24, 25). Endorepellin is proteo-
lytically liberated from perlecan in vivo (27) by the diverse fam-
ily of matrix metalloproteinases (28–34). As an example of
angiogenic fine tuning, matrixmetalloprotease 9 cleaves angio-
static multimerin 2 for vessel sprouting (35).
Structurally, endorepellin is composed of three laminin G–
like domains (LG1/3), each separated by twinEGF-likemodules
(2). Specifically, themodules separating LG2 fromLG3 are sen-
sitive to proteolysis and are cleaved by BMP1/Tolloid-like pro-
teases to release the LG3 domain (36). Furthermore, the crystal
structure of the C-terminal LG3 domain of endorepellin has
been solved (37) and is emerging as an easily accessible bio-
marker (38) for an ever increasing array of diseases (39–48)
including breast cancer (49).
Soluble endorepellin potently “repels” endothelial cell move-
ments, thereby compromising cellmigration and capillarymor-
phogenesis (23). At the level of ligand/receptor interactions,
endorepellin engages in a “dual receptor antagonism” (50) as a
molecular tether, simultaneously ligating VEGFR2 and the
21 integrin (50). The molecular architecture of this hetero-
trimeric complex has been elucidated (50, 51). The proximal
LG1/2 domains interact with the VEGFR2 ectodomain in a
region spanning IgG repeats 3–5 (51, 52). In contrast, the ter-
minal LG3 domain interacts with the -I domain of the 2
subunit of the 21 integrin (50), thereby completing the
bridge. This complex binding paradigm underscores the ex-
quisite specificity (50) and sensitivity (53) of endorepellin
toward endothelial cells. Downstream of dual receptor antago-
nism, endorepellin attenuatesmultiple signaling pathways con-
ducive to a pro-angiogenic program via internalization of the
receptor complex (4). Concurrent with the inhibition of the
phosphatidylinositol 3-kinase/Akt/mammalian target of
rapamycin and activation of AMP-activated protein kinase 
(53, 54), we found that endorepellin evokes endothelial cell
autophagy downstream of VEGFR2, a process concomitantly
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required for angiostasis (55). During autophagy, endorepellin
transcriptionally up-regulates key pro-autophagic genes in-
cluding PEG3, BECN1, andMAP1LC3A (53). However, a com-
prehensive understanding of the autophagic transcriptome
engaged by endorepellin remains ill-defined.
In this study, we generated a custom NanoString probe-set
encompassing 95 autophagy-related genes and probed mRNA
of endothelial cells exposed for 6 h to soluble endorepellin. We
found a unique endorepellin transcriptomic signature consist-
ing of 23 differentially modulated genes. Of these, two genes,
TCHP (mitostatin) and PARK2 (Parkin), were involved in
mitochondrial dynamics and mitophagy. We discovered that
endorepellin stabilized the PINK1/Parkin quality control sys-
tem following mitochondrial depolarization downstream of
VEGFR2. Moreover, we observed that endorepellin evoked co-
localization and binding ofmitostatin to Parkin. These findings
reveal the depth of endorepellin-evoked endothelial cell auto-
phagy via transcriptome remodeling and open possibilities for
extracellularmatrix communication to themitochondria in the
regulation of angiostasis.
Results
Endorepellin differentially regulates the autophagic
transcriptome
Mounting evidence indicates that stable autophagic pro-
grams, such as those influenced by endorepellin, require
sustained transcriptional responses (56–58). Therefore, we
designed a NanoString probe-set to measure the expression of
95 established autophagic genes induced by exposure to nano-
molar concentrations of human recombinant endorepellin.
NanoString is an innovative, state-of-the-art next generation
digital PCR platform that is rapidly gaining attention in many
diverse fields. It utilizes unique molecular barcodes to quanti-
tate the number of user-defined transcripts present within each
sample (59–63).
Early-passage (P3) human umbilical vein endothelial cells
(HUVEC) were treated with highly purified human endorepel-
lin produced in our laboratory (23) expressed in 293-EBNA
cells as a C terminus His6-tagged protein (Fig. S1A) followed by
nickel-nitrilotriacetic acid affinity purification. As determined
by SDS-PAGE, our endorepellin preparations were free of
any co-purifying contaminants (Fig. 1A). We administered
endorepellin in full-serum (nutrient-rich) conditions and
extracted total RNA from vehicle (sterile PBS) and en-
dorepellin-treated HUVEC (n 6/condition). RNA integrity
was analyzed via an Agilent 2200 TapeStation and found to
be ultrapure, intact, and suitable for NanoString transcrip-
tomic analyses (Fig. 1B). We identified 23 differentially reg-
ulated genes that met our inclusion criteria, 2-fold induction
or 50% suppression with a concurrent significance of p 
0.05 (Fig. 1C): 11 up-regulated (Table S1) and 12 down-reg-
ulated targets (Table S2). The pro-autophagic signature
borne out by NanoString provided an unbiased and indepen-
dent confirmation of endorepellin-evoked BECN1 transcrip-
tional induction (Fig. 1C) (53) with a simultaneous down-
regulation of BCL2, a known autophagic inhibitor (Fig. 1C)
(64, 65).
We focused on the coordinate up-regulation of PARK2, which
encodes Parkin, and TCHP, which encodes mitostatin. Parkin is
widely accepted as an RBR E3-ubquitin ligase commonly impli-
cated in autosomal-recessive Parkinson’s disease (66), and mito-
statin is a poorly characterized tumor suppressor gene that we
discovered as a decorin-inducible gene in cancer cells (67, 68).
Importantly, both Parkin and mitostatin have been implicated in
mitochondrial quality control andmitophagy (67, 69–73).
Figure 1. Endorepellin differentially regulates the autophagic transcriptome. A, SDS-PAGE demonstrating purity of human recombinant endorepellin. B,
Agilent 2200 TapeStation-mediated analysis of RNA integrity and purity via capillary gel electrophoresis. C, hierarchical clustering of the 23 differentially
modulated genes that were up-regulated (n  11) or down-regulated (n  12) in HUVEC in vehicle or endorepellin-treated samples. These 23 genes were
filtered and selected on two criteria: 2-fold change (in either directions) and p  0.05. Please refer to Tables S1 and S2 for further details. Data in B and C
represent 6 independent biological replicates of either vehicle (PBS) or endorepellin (6 h, 200 nM)-treated early-passage (P3) HUVEC.
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Endorepellin co–up-regulatesmitostatin and Parkin
downstream of VEGFR2
We validated the selected NanoString targets by immuno-
blotting in two different, genetically normal endothelial cell
types: HUVEC and Telo-HAEC. The latter are human aortic
endothelial cells (HAEC) immortalized by the stable expression
of telomerase (hereafter referred to as HAEC). These cell types
are comparable in terms of possessing stable genomes, similar
exposure to fluid shear stress, and responsiveness to nanomolar
concentrations of endorepellin (50, 51, 54, 74).
We found that endorepellin induced mitostatin and Parkin
over time (Fig. 2,A–C). InHUVEC, both proteins reachedmax-
imal levels at 6 h and remained elevated for up to 12 h. InHAEC,
we observed similar kinetics for mitostatin that noticeably
increased in as little as 1 h (Fig. 2D) and reached a plateau at2
h (Fig. 2, D and E). In contrast, Parkin remained essentially
unchanged until the terminal time point (6 h), where the mag-
nitude of Parkin overlapped with that of mitostatin (Fig. 2, D
and F).
As endorepellin requires both binding to VEGFR2 as well as
its kinase activity to evoke angiostasis and autophagy (4, 21, 75),
we next evaluated whether endorepellin would also require
VEGFR2 signaling for Parkin andmitostatin up-regulation.We
found that blocking the VEGFR2 tyrosine kinase with the selec-
tive and reversible ATP-competitive inhibitor, SU5416 (76, 77),
significantly abrogated endorepellin-evoked Parkin and mito-
statin induction (Fig. 2,G–I). Taken together, these results indi-
cate a time-dependent increase in endorepellin-evoked Parkin
and mitostatin, with differing kinetics, in HUVEC and HAEC
downstream of VEGFR2.
Endorepellin evokesmitochondrial depolarization via LG1/2
It is well established that Parkin is recruited to depolarized
and/or damaged mitochondria (66, 79, 80). Thus, we hypothe-
sized that endorepellin could compromise mitochondrial
membrane potential integrity via Parkin modulation. We
assessed the effects of endorepellin on mitochondrial mem-
brane potential (m) using JC-1, a lipophilic cationic dye that
is sensitive to voltage fluctuations. JC-1 accumulates within the
inner mitochondrial membrane in response to the m. At a
low m (e.g. loss of membrane potential), JC-1 is monomeric
and exhibits green fluorescence. However, high levels of JC-1
accumulate (proportional to a high m) and lead to the for-
mation of JC-1 aggregates that shifts the JC-1 emission spec-
trum toward red fluorescence (81). To this end, we treated
HUVEC with endorepellin in parallel with carbonyl cyanide
m-chlorophenylhydrazine (CCCP) or carbonyl cyanide p-trif-
luoromethoxyphenylhydrazone (FCCP), both known iono-
phores that uncouple ATP synthesis by transporting hydrogen
ions across the mitochondrial membranes and dissipating the
proton motive force.
Figure 2. Endorepellin co–up-regulates mitostatin and Parkin downstream of VEGFR2. A–C, immunoblot and quantification of mitostatin and Parkin in
HUVEC treated with endorepellin over time. D–F, identical experiments as in A–C in HAEC. G–I, immunoblot and quantification of mitostatin and Parkin in
HUVEC treated in combination with endorepellin or SU5416 (30M) for 6 h. GAPDH served as an internal loading control for all immunoblots. Quantifications
presented in B, C, E, F, H, and I are representative of at least three to four independent biological replicates in HUVEC or HAEC. Statistical analyses presented in
H and Iwere calculated via one-way ANOVA.
Endorepellin evokes a pro-autophagic gene signature
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We found a profound loss of m as determined by JC-1
staining (Fig. 3A) and further quantification of the green (depo-
larized, JC-1 monomers) and red (polarized, JC-1 aggregates)
fluorescence (Fig. 3B). The magnitude of depolarization was
not significantly different between endorepellin and CCCP
(p  0.652) or endorepellin and FCCP (p  0.443), indicating
comparable m efficiency and a potential common pathway.
In an effort to identify the domains required for endorepellin
binding to VEGFR2 (51), we generated two endorepellin frag-
ments containing LG1/2 (composed of LG1, LG2, and both sets
of the twin EGF-like modules) (Fig. S1A) or simply LG3 alone
(Fig. S1A). We have previously shown that LG1/2 binds the
IgG3–5 repeats of the VEGFR2 ectodomain, whereas LG3 binds
the 21 integrin (4, 52, 75, 82). Thus, we employed these frag-
ments to dissect which bioactive modules of endorepellin are
responsible for transducingmpertinent information. Nota-
bly, LG1/2 resulted in a robust m akin to endorepellin (Fig.
3C). In contrast, LG3 was unable to evoke such a response (Fig.
3C). Quantifying the fluorescence intensity for both channels,
we found a significant depolarization upon LG1/2 treatment
(Fig. 3D) that was not statistically significantly different from
endorepellin (p 0.769), whereas LG3 was unchanged relative
to control levels (p 0.905). As m was unchanged by LG3,
we surmised blocking the 21 integrin with a specific mAb,
mAb1998Z (53, 83), should have no apparent effect on
endorepellin-evoked mitochondrial depolarization. Intrigu-
ingly, we found that endorepellin in the presence ofmAb1998Z
prevented m when compared with endorepellin alone
(Fig. S2, A and D). We validated endorepellin and mAb199Z
with phallodoin staining to visualize the actin cytoskeleton.
Endorepellin evokes actin dissolution via the 21 integrin
(83), specifically LG3 (51, 82). Indeed, abrogating binding of
endorepellin to the 21 integrin inhibited actin dissolution
(Fig. S2B), thereby functionally validatingmAb1998Z. Next, we
combined LG1/2 withmAb1998Z and found loss of membrane
potential independent of the 21 integrin blocking activities
of the antibody (Fig. S2, C and E). Collectively, these data rein-
force the concept that VEGFR2 is the primary receptor for
endothelial cell m, irrespective of the 21 integrin. These
data indicate that LG1/2 is sufficient for mitochondrial depo-
larization and is most likely transduced by VEGFR2.
Endorepellin-evokedmodulation of PINK1 andmitofusin 2
Having established that endorepellin compromisesm,we
next examined whether endorepellin would also affect PINK1,
an effector kinase stabilized in response tomitochondrial depolar-
ization (84), which works in synergy with Parkin (66). Among the
targets of PINK1 ismitofusin 2 that acts as a receptor for recruited
Parkin to cull damaged mitochondria (85). We found a rapid and
sustained accumulation of PINK1 (within 30 min) following
Figure 3. LG1/2 domain of endorepellin is sufficient for mitochondrial depolarization. A and B, representative fluorescence micrographs depicting live
cell imaging of HUVEC after incubationwith endorepellin (6 h), CCCP (1 h, 30M), or FCCP (10min, 500 nM) inA, or endorepellin (6 h), LG1/2 (6 h, 150 nM), or LG3
(6 h, 150 nM) in B. HUVECwere cultured in nutrient-richmedia and incubatedwith JC-1 (20min, 7.5M) to assessmitochondrial membrane potential. Scale bar
80m. C andD, quantification of polarized (green) comparedwith depolarized (red) mitochondria as shown in A or B, respectively. E and F, immunoblot and
quantification of mitofusin 2 and PINK1 in HUVEC treated with endorepellin over time. G, analyses of PINK1 orMFN2 in HUVEC treated with endorepellin over
time. For live cell imaging in A and B, at least 10 fields per condition were acquired for each of three to four biological replicates in HUVEC. Quantifications in C
and D are representative of three to four independent biological replicates. GAPDH served as an internal loading control for immunoblots in E and are
representative of four independent biological replicates. Immunoblot quantifications in F are representative of four independent biological replicates. Gene
expression analyses presented inGhavebeennormalized toACTBand represent four independentbiological replicates. Statistical analyses presented inC and
Dwere calculated via one-way ANOVA.
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endorepellin treatments (Fig. 3, E and F). This was followed, at
later time points, by a concomitant accumulation of mitofusin 2
protein (Fig. 3, E and F). We complemented these results in
HUVECwithCCCPandFCCPandfoundcomparable increases in
both PINK1 over time with CCCP (Fig. S1B) and PINK1 tran-
siently with FCCP (Fig. S1C) in HUVEC. Notably, these increases
in PINK1 and mitofusin 2 occurred independently of transcrip-
tion, as no modulation in the mRNA profiles of either PINK1 or
MFN2was found (Fig. 3G).Thus,wehave identifiedanoveldown-
streamsignaling pathway for endorepellin that triggersmitochon-
drial depolarization via the LG1/2 domain with a consequent
increase in PINK1 andmitofusin 2, independent of transcription.
VEGFR2 is required for endorepellin-evokedmitochondrial
depolarization
Having ascertained that LG1/2 is sufficient formitochondrial
depolarization, we evaluated whether the tyrosine kinase of
VEGFR2 is required. Using JC-1 to assess the effects of
endorepellin on m, we found that blocking VEGFR2 kinase
with SU5416 significantly blocked endorepellin-evoked m
(Fig. 4, A and B). Furthermore, treatment with SU5416 alone
had no effect, suggesting an active processmediated exclusively
upon endorepellin-binding VEGFR2 (Fig. 4, A and B). Next, we
utilized siRNA to transiently deplete VEGFR2. Transient trans-
fection of a scramble siRNA sequence complexed with a lipid-
based carrier did not cause significant damage or undue stress
(compare Fig. 4, A with C). After validating VEGFR2 depletion
with a pool of 3–5 targeting siRNAoligonucleotides (Fig. 4D) with
a resulting knockdownof65% (Fig. 4E), we found that loss of the
receptor recapitulated the effect of pharmacological inhibition
with SU5416 (Fig. 4C) and significantly attenuatedm(Fig. 4F).
Thus, we have identified a functional and mechanistic role for
VEGFR2 in transducing information from endorepellin for mito-
chondrial depolarization in endothelial cells.
Parkinandmitostatin colocalize inaVEGFR2-dependentmanner
Next, we utilized confocal laser microscopy to determine
whether there is any co-localization of Parkin, and mitostatin,
Figure 4. VEGFR2 is required for endorepellin-evoked mitochondrial depolarization. A, representative fluorescence micrographs depicting live cell
imaging of HUVEC after incubation with endorepellin in combination with SU5416 after staining with JC-1. HUVEC were cultured in nutrient-rich media. B,
quantification of polarized (green) comparedwith depolarized (red)mitochondria as shown inA.C, representative fluorescencemicrographs depicting live cell
imaging of HUVEC after transient transfection of scramble siRNA (siScramble) or siVEGFR2 followed by endorepellin (6 h). D and E, immunoblot and quantifi-
cation of VEGFR2 silencing in HUVEC. F, quantification of polarized (green) compared with depolarized (red) mitochondria as shown in C. Scale bar in A and C,
80m. For live cell imaging in A and C, at least 10 fields per condition were acquired for each of four biological replicates in HUVEC. Quantifications in B and
F are representative of four independent biological replicates. GAPDHserved as an internal loading control for immunoblots inD andare representative of four
independent biological replicates. Immunoblot quantifications in E are representative of four independent biological replicates. Statistical analyses presented
in B and Fwere calculated via one-way ANOVA.
Endorepellin evokes a pro-autophagic gene signature
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and whether mitostatin and Parkin interact in solution. More-
over, mitostatin bindsmitofusin 2 at specialized regions known
as mitochondrial associated membranes juxtapositions be-
tween the mitochondria and endoplasmic reticulum (86).
Under basal conditions, we detected very little Parkin stain-
ing (Fig. 5A) in agreement with the biochemical data showing
low levels detected by immunoblot (cf. Fig. 2A). Mitostatin
immunoreactivity was considerablymore robust with a profuse
staining pattern throughout the cell and nuclear compartments
(Fig. 5A).We found no co-localization of mitostatin and Parkin
under resting conditions. Exogenous endorepellin caused a
marked increase in Parkin throughout the cytosol and a striking
co-localization of mitostatin and Parkin (Fig. 5B) in clearly
delineated punctate structures (Fig. 5B, inset). As seen above
with them assays, SU5416 alone had no effect on the distri-
bution of mitostatin and Parkin (Fig. 5C). However, SU5416
completely blocked the effect of endorepellin on mitostatin
and Parkin co-localization (Fig. 5D). These data suggest that
VEGFR2 controls the association of mitostatin and Parkin in
response to endorepellin.
Next, we corroborated our imaging study with immunopre-
cipitation data. Using the anti-mitostatin antibody, we success-
fully immunoprecipitatedmitostatin. Lysates exposed to a con-
trol rabbit IgG-G2 displayed no such immunoprecipitates (Fig.
5E), validating the specificity of our antibody. Importantly, we
found an exclusive interaction ofmitostatinwith Parkin follow-
ing endorepellin treatment (Fig. 5E), thereby confirming our
confocal microscopy results. We also confirmed the previously
reported (86) basal association of mitostatin with mitofusin 2
(Fig. 5E) but found no altered interactions upon endorepellin
treatment (Fig. 5E).
Next, we performed reciprocal co-immunoprecipitations of
Parkin (Fig. 5F). Using a control mouse IgG-G2, we found no
immunoprecipitating bands, substantiating the specificity of
our antibody. In agreementwith the immunofluorescence data,
we found an exclusive association of Parkin with mitostatin
following endorepellin treatment (Fig. 5F). However, immuno-
blotting for mitofusin 2 revealed a modest decrease in the asso-
ciation of Parkin andmitofusin 2 not seen whenmitostatin was
immunoprecipitated (Fig. 5F). These data suggest a differential
Figure 5. Parkin andmitostatin co-localize in a VEGFR2-dependentmanner. A–D, confocal laser microscopy depictingmitostatin (green) and Parkin (red)
following endorepellin (6 h) alone or in combinationwith SU5416 in HUVEC. Nuclei (blue) were visualizedwith 4,6-diamidino-2-phenylindole (DAPI). Scale bar
10mm. Insets denote 3 times digitally magnified images from the area demarcated by the solid white box. E and F, representative images of co-immunopre-
cipitations of HUVEC treated with endorepellin and immunoprecipitated for mitostatin (E) or Parkin (F) and immunoblotted for mitofusin 2, Parkin, or mito-
statin. G and H, quantification of mitofusin-2 following mitostatin immunoprecipitation (as in E) or Parkin immunoprecipitation (as in F). For confocal micros-
copy inA-D, at least five fields/conditionwere obtained for at least two independent biological replicates in HUVEC. Immunoblots in E and F are representative
of three independent biological replicates in HUVEC. Mitofusin-2 quantifications in G and H are representative of three independent biological replicates in
HUVEC. Statistical analyses provided by two-tailed Student’s t test.
Endorepellin evokes a pro-autophagic gene signature
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binding ofmitostatin andmitofusin 2 over Parkin in endothelial
cells. Quantification of mitofusin-2 following immunoprecipi-
tation of mitostatin (Fig. 5G) or Parkin (Fig. 5H) further con-
firmed these results.
Collectively, our results identify an exclusive association
between mitostatin and Parkin after exposure to endorepellin.
Furthermore, the formation of the mitostatin-Parkin com-
plexes require the physical presence ofVEGFR2 and the activity
of its kinase.
Endorepellin evokes autophagic flux, but not ofmitofusin 2 or
mitostatin
We have determined that endorepellin is capable of increas-
ing the rate of endothelial cell autophagy (55) by examining
autophagic flux of established markers (such as LC3-II) (87) in
the presence of chloroquine. Here, we evaluated the effects of
bafilomycin A1, a V-type ATPase inhibitor that prevents fusion
between the autophagosome and lysosome, in conjunctionwith
endorepellin thereby permitting analyses of the rates of accu-
mulated autophagic markers. Treatment with bafilomycin A1
(100 nM) alone resulted in a marked accumulation of LC3-II
(Fig. 6, A and B) and p62/SQSTM1 (Fig. 6, A and C). Intrigu-
ingly, under basal conditions at two different concentrations,
bafilomycinA1 had no discernible effects onmitofusin 2 (Fig. 6,
A and D) or mitostatin (Fig. 6, A and E).
In congruence with our previous study (55), endorepellin, in
combination with bafilomycin A1, significantly enhanced
autophagic flux as per LC3-II analysis (Fig. 6, A and B). How-
ever, under the same conditions, we found no significant
increase (or change) in the levels of p62/SQSTM1 (Fig. 6,A and
C). Likewise, as per the aforementioned data (cf. Figs. 2 and 3E),
endorepellin evoked mitofusin 2 (Fig. 6, A and D) and mitosta-
tin (Fig. 6, A and E). Intriguingly, a combination treatment of
endorepellin and bafilomycin A1 increased neither mitofusin 2
(Fig. 6, A and D) nor mitostatin (Fig. 6, A and E) above that of
simply endorepellin alone. Parkin responded in a similar man-
ner (data not shown).
In summary, we recapitulated endorepellin-enhanced
autophagic flux in endothelial cells. However, the newly identi-
fied targets were not sensitive to basal autophagic flux nor aug-
mented flux as stimulated by endorepellin.
Discussion
We discovered a unique endorepellin-evoked autophagic
signature following digital PCR profiling of a specific subset of
the endothelial cell transcriptome. Querying our custom
probe-set, we found 23 differentially regulated genes. Among
the targets, several genes including the distinct regulation of
BECN1 and the autophagic inhibitor BCL2 (53, 64, 65, 88, 89)
independently confirmed the robustness of our dataset and sig-
nals a shift to a pro-autophagic program. Beclin-1 is phosphor-
ylated by Akt leading to autophagic inhibition (90). We discov-
ered that endorepellin inactivates the phosphatidylinositol
3-kinase/Akt pathway (54) as a potentialmechanism of Beclin 1
derepression and resultant autophagic initiation. Beclin 1
appears to be governed by RTKs (91), designating a conver-
gence on RTKs by soluble matrix components in evoking
autophagy (92). The Beclin-1 homologue BECN2, also impli-
cated in autophagy and metabolism (93), was further identified
as an endorepellin-inducible gene.
Moving forward, endorepellin co–up-regulates the mRNA
and protein of PARK2 and TCHP (encoding Parkin and mito-
statin, respectively), effectors implicated in mitochondrial
homeostasis and mitophagy (66, 73). Induction of Parkin and
mitostatin depended on the VEGFR2 tyrosine kinase, indicat-
ing partial agonism, thereby allowing us to refine themodel as a
“dual receptor partial agonism” rather than strict dual receptor
antagonism.
Given that Parkin is recruited to depolarized and/or dam-
aged mitochondria for Parkin-mediated mitophagy (94), we
discovered that endorepellin-evoked mitochondrial depolar-
ization. Intriguingly, depolarization occurred with the same
magnitude as CCCP and FCCP, known electron transport
chain uncouplers. Functionally, and mechanistically, the mod-
Figure 6. Endorepellin evokes autophagic flux, but not of mitofusin 2 or mitostatin. A, representative immunoblots of mitofusin 2, mitostatin, p62/
SQSTM1, LC3-I/-II, and GAPDH following endorepellin (6 h) alone or in combination with bafilomycin A1 (100 nM). B–E, quantification of targets as shown in A.
GAPDH served as an internal loading control for immunoblots in A and are representative of four independent biological replicates. Immunoblot quantifica-
tions in B-E are representative of four independent biological replicates. Statistical analyses presented in B and Cwere calculated via one-way ANOVA.
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ular architecture of endorepellin permitted us to identify the
LG1/2/VEGFR2 interaction, but not the LG3/21 interaction,
as sufficient for the loss of mitochondrial membrane potential.
Intriguingly, a combination of mAb1998Z with endorepellin
significantly blocked m. This might be due to a positioning
role of the 21 integrin for full-length endorepellin to inter-
act with VEGFR2. This is reinforced by LG1/2 in conjunction
with mAb1998Z efficiently depolarizing the mitochondria
and lack of response of LG3 alone. Alternately, endorepellin
may have been blocked due to steric hindrance from the
antibody binding to the I-domain of the 2 subunit and
unabridged endorepellin.
Whether mitochondrial depolarization occurs downstream
of VEGFR2 in response to intracellular calcium mobilization
(95, 96) remains unknown. However, based on our previous
work (54) thismode of action seems unlikely. Endorepellin pre-
vents phosphorylation of VEGFR2 at Tyr1175, a key phospho-
site for phospholipase C- recruitment; thereby, precluding the
formation of diacylglycerol and inositol 1,4,5-triphosphate.
The latter being critical for calcium flux downstream of RTK
signaling. Concurrent with mitochondrial depolarization was a
rapid stabilization of PINK1 (94) and temporal accumulation of
mitofusin 2, a mitostatin binding partner and Parkin receptor
(85, 86, 97). Increased amounts of mitofusin 2 act to juxtapose
Parkin near PINK1 for subsequent activation (97) and clearance
of the damaged organelle.
The co-localized mitostatin/Parkin positive puncta formed
in response to endorepellin, downstream of VEGFR2 signaling,
was decidedly more discreet in morphology than autophago-
somes evoked by endorepellin (53, 55). This interaction
appeared to formonly after stimulation, as no co-localization or
bindingwas found under basal conditions. Using the previously
published interaction between mitostatin and mitofusin 2 (86)
as a positive control for our immunoprecipitation, we found an
increased association betweenmitostatin andmitofusin 2 post-
endorepellin treatment. Resolving the precise interactions and
deciphering the biological consequence of the mitostatin/Par-
kin interaction and increased binding ofmitostatin tomitofusin
2 will require future studies as it pertains to mitochondrial
homeostasis.
The observation that Parkin, mitostatin, and mitofusin 2 are
not substrates of basal autophagic flux or endorepellin-evoked
flux in endothelial cells implies their function in an alternate
pathway. Indeed, mitofusin 2, despite being involved in
mitophagy, is sent to the 26S proteasome for degradation by
Parkin (70). Emerging evidence posits a cooperation between
the autophagic machinery and the ubiquitin-proteasome sys-
tem for competentmitochondrial clearance viamitophagy (98).
Considering that mitostatin-Parkin andmitostatin-mitofusin 2
are complexed, these protein complexes may thereby bypass
the autophagosomal system and are instead being targeted for
degradation.
In conclusion, we discovered a unique endorepellin-depen-
dent transcriptomic signature revealing a broad remodeling of
genes to favor the autophagic response. Furthermore, for the
first time, we found evidence of endorepellin regulating mito-
chondrial dynamics. These findings have widened our under-
standing of matrix-driven autophagy and provide a framework
conducive for a deeper understanding of this conserved
process.
Experimental procedures
Cells, chemicals, and reagents
HUVECwere obtained from Lifeline Cell Technology (Fred-
erick,MD), grown in basal medium and supplemented with the
VascuLife EnGS LifeFactors Kit (Lifeline Cell Technology).
HUVEC were used within the first five passages. Telo-HAEC
were obtained from American Type Cell Cultures (Manassas,
VA) and cultured in EGM-2 SingleQuot Kit Supplements and
Growth Factors (Lonza). Rabbit polyclonal antibodies against
GAPDH, PINK1, VEGFR2, and p62/SQSTM1 were obtained
from Cell Signaling Technology. Rabbit polyclonal anti-LC3B,
SU5416, CCCP, FCCP, and JC-1 were purchased from Sigma.
The horseradish peroxidase-conjugated goat anti-rabbit, don-
key anti-mouse secondary antibodies, and negative rabbit and
mouse IgG-G2 immunoprecipitation antibodies were obtained
from EMDMillipore (Billerica, MA). Mouse monoclonal anti-
bodies against Parkin and mitofusin 2 were obtained from Cell
Signaling Technology. Mouse mAb against -tubulin was pur-
chased from Santa Cruz Biotechnology. A custom rabbit poly-
clonal antibody against mitostatin was generated as described
elsewhere (73). All primary antibodies were used at 1:1000 dilu-
tion in 1% BSA/TBST, except for GAPDH, which was used at
1:10,000 and -tubulin, which was used at 1:400. For immuno-
fluorescence, primary antibodies were used at 1:200 in 1% BSA
inPBS. Secondary antibodies for chemiluminescencewere used
at 1:5,000 in the same buffer as above. SuperSignal West Pico
enhanced chemiluminescence substrate was purchased from
Thermo Fisher Scientific. The purification and validation of
human recombinant endorepellin have been described and
demonstrated above. Purification and validation of human
recombinant LG1/2 and LG3 are described elsewhere (51).
Highly purified endorepellin was used at 200 nM, whereas
LG1/2 and LG3was used at 150 nM throughout the study. Orig-
inal, whole blots can be found in Fig. S3.
NanoString transcriptomic analysis
NanoString nCounter reporter probe-sets were designed to
detect expression changes in a manually curated set (n 95) of
established autophagy genes available in the literature at the
time of probe-set synthesis.
Early passage HUVEC (P3) were treated (n 6) with vehicle
(PBS) or endorepellin (6 h, 200 nM). RNA was extracted and
validated by an Agilent 2200 TapeStation before entering the
workflow for NanoString analyses. Samples were processed
(including RNA validation) at the Genomic Pathology Labora-
tory (Thomas Jefferson University), following the nCounter
Gene Expression protocol. Briefly, total RNA was incubated at
65 °C with reporter and capture probes in hybridization buffer.
Capture probes were purified and analyzed on the nCounter
Digital Analyzer. The number ofmolecules of a given transcript
in the endorepellin-treated samples was determined by nor-
malizing detected transcript counts to the geometric mean of
control RNA sequences and a set of control genes (n 5) that
did not show evidence of altered expression by endorepellin.
Significant differences between vehicle and endorepellin (p 
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0.05) were detected by paired two-tailed t tests comparing the
paired mean values for each gene (averaged across samples
within each condition) between each condition.
Transient RNAi-mediated silencing
HUVEC were transiently transfected using Lipofectamine
RNAiMAX (Life Technologies) mixed with siRNA against
Homo sapiens VEGFR2 (Santa Cruz Biotechnology). Scrambled
siRNA (Santa Cruz Biotechnology) served as a control for
all siRNA experiments presented herein. The protocol for
siRNA-mediated silencing is described elsewhere (99).
Mitochondrial membrane potential
At least three individual assays were performed in HUVEC
using the mitochondrial dye JC-1. HUVEC were grown in four
chambered glass slides coated with 0.1% gelatin for 24 h at
37 °C. Cells were treated as per the experimental conditions
described herein. CCCP was used at 30 M and FCCP used at
500 nM for the last hour or 10 min before staining with JC-1,
respectively. Each chamber was incubated with JC-1 (7.5 M)
for 20min. Cells were washed three times with PBS and imaged
live using a Leica DM5500B microscope. All the images were
procured using the same exposure, gain, and intensity.
Immunofluorescence and confocal lasermicroscopy
Typically, 5 	 104 HUVEC were plated on 0.2% gelatin-
coated 4-well chamber slides (Nunc, Thermo Scientific) and
grown to full confluence in their growth media at 37 °C. Cells
were treated as per the experimental conditions contained
herein, and immunofluorescence was performed as previously
done (100, 101). Slides were incubatedwith conjugated second-
ary antibodies such as: goat anti-rabbit IgG Alexa Fluor 488
and goat anti-mouse IgG Alexa Fluor 564 (Invitrogen). Nuclei
were visualized with 4,6-diamidino-2-phenylindole (Vector
Laboratories). JC-1 live cell immunofluorescence images were
acquired with a 	10 objective on a LEICA DM5500B micro-
scope installedwith the LeicaApplication suite, using advanced
fluorescence version 1.8 software (Leica Microsystems, Frank-
furt, Germany). Confocal analyses were carried out utilizing a
	63, 1.3 oil-immersion objective of a Zeiss LSM-780 confocal
laser-scanning microscope with Zen Imaging Software. A full
description of the immunofluorescence and confocal laser
microscopy protocol can be found elsewhere (78).
Quantitative real-time PCR
Expression analysis by quantitative real-time PCR was car-
ried out on subconfluent six-well plates seeded with2	 105
ofHUVECandharvested inTRIzol reagent (Invitrogen) follow-
ing the appropriate experimental conditions. Gene expression
analysis was performed on a Roche LightCycler 480-II and cal-
culated with the comparative Ctmethod. A full description can
be found in Ref. 26.
Quantification and statistical analysis
Immunoblots were quantified by scanning densitometry
using Scion ImageJ software (NIH). Graphs were generated
using Sigma Stat 3.10. Experimentswith three ormore compar-
ison groups were subjected to one-way ANOVA followed by a
Bonferroni post hoc test. Differences among the conditions
were considered significant at p 0.05.
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